度普利尤单抗改善手足特应性皮炎体征、症状、生活质量和工作效率:3期随机双盲安慰剂对照试验结果
这项多中心3期试验纳入133例中重度手足特应性皮炎患者,随机接受度普利尤单抗单药或安慰剂治疗16周。
要点
- 度普利尤单抗单药治疗16周可显著改善手足特应性皮炎的疾病严重度。
- 瘙痒、疼痛、生活质量、睡眠等预设次要终点均达到,安全性可接受。
核心结论
- 度普利尤单抗单药治疗在手足特应性皮炎的多个领域带来显著改善,且安全性可接受,支持其作为这一难治情况的全身治疗选择。
研究设计与样本
- 多中心3期随机双盲安慰剂对照试验,纳入成人及青少年中重度手足特应性皮炎患者,随机接受度普利尤单抗单药(获批用于泛发性特应性皮炎的方案)或匹配安慰剂。
- 共133例患者(成人106例,青少年27例)随机分配至度普利尤单抗组(n=67)或安慰剂组(n=66)。
主要发现
- 所有其他预设终点均达到,安全性与其他特应性皮炎患者中的已知度普利尤单抗特征一致。
关键数值与推荐
- 主要终点:第16周达到手足研究者总体评估评分0或1的患者比例。
临床怎么用
- 对于中重度手足特应性皮炎患者,度普利尤单抗单药可作为全身治疗选择,改善体征、症状、生活质量和工作效率。
局限性
- 研究为短期16周治疗期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite high disease burden, systemic treatment options for patients with atopic hand and/or foot dermatitis (H/F AD) are limited. OBJECTIVES: To evaluate efficacy and safety of dupilumab in H/F AD using specific instruments for assessing disease severity on hands and feet. METHODS: In this multicenter phase 3 trial, adults and adolescents with moderate-to-severe H/F AD were randomized to dupilumab monotherapy (regimen approved for generalized AD), or matched placebo. The primary endpoint was proportion of patients achieving Hand and Foot Investigator's Global Assessment score 0 or 1 at week 16. Secondary prespecified endpoints assessed the severity and extent of signs, symptom intensity (itch, pain), quality of life, and sleep. RESULTS: A total of 133 patients (adults = 106, adolescents = 27) were randomized to dupilumab (n = 67) or placebo (n = 66). At week 16, significantly more patients receiving dupilumab (n = 27) than placebo (n = 11) achieved Hand and Foot Investigator's Global Assessment score 0 or 1 (40.3% vs 16.7%; P = .003). All other prespecified endpoints were met. Safety was consistent with the known AD dupilumab profile. LIMITATIONS: Short-term, 16-week treatment period. CONCLUSION: Dupilumab monotherapy resulted in significant improvements across different domains of H/F AD with acceptable safety, supporting dupilumab as a systemic treatment approach for this often difficult to treat condition.
引用
- Simpson EL, Silverberg JI, Worm M, et al. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024. PMID: 38296199. doi:10.1016/j.jaad.2023.12.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。